Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy D Miller

Showing results (11-20 of 205) with videos related to

Pageof 21
Sort By:
Cancer Investigation|November 21, 2007
Antiangiogenic agents in breast cancerJohn T Salter, Kathy D Miller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
<i>JCO</i> Turns 40Kathy D Miller, Jonathan W Friedberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Introducing Clinical Trial UpdatesKathy D Miller, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 12, 2004
Breast cancer: the role of angiogenesis and antiangiogenic therapyKathy D Miller, Carrie L Dul
Current Problems in Cancer|April 19, 2002
Angiogenesis and antiangiogenic therapyGeorge W Sledge, Kathy D Miller
Breast Cancer (Tokyo, Japan)|January 29, 2008
Development of new targeted therapies for breast cancerDanielle M Doyle, Kathy D Miller
Clinical Breast Cancer|January 23, 2009
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancerFoluso O Ademuyiwa, Kathy D Miller
Cancer Cell|September 6, 2008
Redefining the target again: chemotherapeutics as vascular disrupting agents?Yesim Gokmen-Polar, Kathy D Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
The potential and suitability of 2-methoxyestradiol in cancer therapyCarolyn Sidor, Robert D'Amato, Kathy D Miller
The Lancet. Oncology|October 3, 2012
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentBryan P Schneider, Fei Shen, Kathy D Miller
Pageof 21

Showing results (11-20 of 205) with videos related to

Sort By:
Pageof 21
Cancer Investigation|November 21, 2007
Antiangiogenic agents in breast cancerJohn T Salter, Kathy D Miller
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2022
<i>JCO</i> Turns 40Kathy D Miller, Jonathan W Friedberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2022
Introducing Clinical Trial UpdatesKathy D Miller, Jonathan W Friedberg
Hematology/Oncology Clinics of North America|October 12, 2004
Breast cancer: the role of angiogenesis and antiangiogenic therapyKathy D Miller, Carrie L Dul
Current Problems in Cancer|April 19, 2002
Angiogenesis and antiangiogenic therapyGeorge W Sledge, Kathy D Miller
Breast Cancer (Tokyo, Japan)|January 29, 2008
Development of new targeted therapies for breast cancerDanielle M Doyle, Kathy D Miller
Clinical Breast Cancer|January 23, 2009
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancerFoluso O Ademuyiwa, Kathy D Miller
Cancer Cell|September 6, 2008
Redefining the target again: chemotherapeutics as vascular disrupting agents?Yesim Gokmen-Polar, Kathy D Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
The potential and suitability of 2-methoxyestradiol in cancer therapyCarolyn Sidor, Robert D'Amato, Kathy D Miller
The Lancet. Oncology|October 3, 2012
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentBryan P Schneider, Fei Shen, Kathy D Miller
Pageof 21